Funding for this research was provided by:
LEO Pharma (LEO Pharma)
Henry Kjellén Memorial Fund (2018)
Umea University
Article History
Accepted: 14 March 2023
First Online: 29 April 2023
Declarations
:
: The authors declare the following financial interests/personal relationships which may be considered as potential. Anders Själander was the principal investigator of the RE-VERSE AD study in Sweden and has received consultancy and lecture fees from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck Sharp and Dohme, Takeda Pharma and Pfizer. The other authors have no relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. The Swedish Ethical Review Authority approved the study (2018-54-31 M).
: was obtained in written or oral form from all participants included in the study. The telephone interview was conducted as a part of a routine follow-up by the Anticoagulation Clinic in Sundsvall Sweden.